EA201890524A1 - (s,e)-3-(6-аминопиридин-3-ил)-n-((5-(4-(3-фтор-3-метилпирролидин-1-карбонил)фенил)-7-(4-фторфенил)бензофуран-2-ил)метил)акриламид для лечения рака - Google Patents
(s,e)-3-(6-аминопиридин-3-ил)-n-((5-(4-(3-фтор-3-метилпирролидин-1-карбонил)фенил)-7-(4-фторфенил)бензофуран-2-ил)метил)акриламид для лечения ракаInfo
- Publication number
- EA201890524A1 EA201890524A1 EA201890524A EA201890524A EA201890524A1 EA 201890524 A1 EA201890524 A1 EA 201890524A1 EA 201890524 A EA201890524 A EA 201890524A EA 201890524 A EA201890524 A EA 201890524A EA 201890524 A1 EA201890524 A1 EA 201890524A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- fluoro
- phenyl
- pharmaceutically acceptable
- acceptable salt
- compound
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- -1 4- (3-Fluoro-3-Methylpyrrolidin-1-Carbonyl) phenyl Chemical group 0.000 title 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 title 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562206472P | 2015-08-18 | 2015-08-18 | |
| PCT/US2016/047566 WO2017031323A1 (en) | 2015-08-18 | 2016-08-18 | (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201890524A1 true EA201890524A1 (ru) | 2018-07-31 |
Family
ID=56799634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201890524A EA201890524A1 (ru) | 2015-08-18 | 2016-08-18 | (s,e)-3-(6-аминопиридин-3-ил)-n-((5-(4-(3-фтор-3-метилпирролидин-1-карбонил)фенил)-7-(4-фторфенил)бензофуран-2-ил)метил)акриламид для лечения рака |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10363247B2 (https=) |
| EP (1) | EP3337797A1 (https=) |
| JP (1) | JP2018528196A (https=) |
| CN (1) | CN108137563A (https=) |
| AU (1) | AU2016308829A1 (https=) |
| CA (1) | CA2995380A1 (https=) |
| EA (1) | EA201890524A1 (https=) |
| HK (1) | HK1255438A1 (https=) |
| IL (1) | IL257422A (https=) |
| MA (1) | MA42655A (https=) |
| MX (1) | MX2018001979A (https=) |
| WO (1) | WO2017031323A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3016946B1 (en) | 2013-07-03 | 2022-10-12 | Karyopharm Therapeutics Inc. | Substituted benzofuranyl and benzoxazolyl compounds and pharmaceutical uses thereof |
| WO2015042414A1 (en) | 2013-09-20 | 2015-03-26 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
| HK1255438A1 (zh) | 2015-08-18 | 2019-08-16 | 卡尔约药物治疗公司 | 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 |
| WO2017117447A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
| CN111171233B (zh) * | 2020-01-17 | 2023-03-31 | 吉林师范大学 | 一种新型磁性薄层印迹膜的制备方法及用途 |
| CN115569196B (zh) * | 2020-02-26 | 2024-06-18 | 上海科技大学 | 多酚类物质在抗冠状病毒中的应用 |
| CN114507215B (zh) * | 2020-11-14 | 2024-09-13 | 成都海博为药业有限公司 | 一种作为pak4激酶抑制剂的化合物及其制备方法和应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| DE19818044A1 (de) | 1998-04-22 | 1999-10-28 | Klinge Co Chem Pharm Fab | Verwendung von Vitamin-PP-Verbindungen |
| ATE345341T1 (de) | 2001-07-19 | 2006-12-15 | Pfizer Italia Srl | Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel |
| EP1348434A1 (en) | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
| US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| US7078419B2 (en) | 2003-03-10 | 2006-07-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
| US7638540B2 (en) | 2003-05-29 | 2009-12-29 | The New Industry Research Organization | Benzofuran compound and medicinal composition containing the same |
| US7420066B2 (en) | 2003-08-07 | 2008-09-02 | Bayer Pharmaceuticals Corporation | Benzofuran derivatives useful for treating hyper-proliferative disorders |
| US7368476B2 (en) | 2004-04-07 | 2008-05-06 | Pharmacyclics, Inc. | Hydroxamates as therapeutic agents |
| MY149038A (en) | 2004-05-26 | 2013-07-15 | Eisai R&D Man Co Ltd | Cinnamide compound |
| TW200616613A (en) | 2004-10-05 | 2006-06-01 | Shionogi & Co | Biaryl derivatives |
| JPWO2006054793A1 (ja) | 2004-11-19 | 2008-06-05 | 財団法人新産業創造研究機構 | ベンゾフラン化合物、およびそれを含有してなる医薬組成物 |
| JP2008534664A (ja) | 2005-04-06 | 2008-08-28 | アストラゼネカ アクチボラグ | 置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用 |
| MX2007013065A (es) | 2005-04-22 | 2008-01-14 | Wyeth Corp | Derivados de dihidrobenzofurano y usos de los mismos. |
| US20080020413A1 (en) | 2006-03-29 | 2008-01-24 | Columbia University | Crystalline visfatin and methods therefor |
| WO2008026018A1 (en) | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
| EP2003118A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Zimtsäurederivate als Modulatoren des EP2-Rezeptors |
| US8173677B2 (en) | 2007-09-26 | 2012-05-08 | Gemin X Pharmaceuticals Canada Inc. | Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
| CA2701071C (en) | 2007-09-26 | 2018-03-27 | Gemin X Pharmaceuticals Canada Inc. | Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
| EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| FR2943669B1 (fr) | 2009-03-24 | 2011-05-06 | Sanofi Aventis | Derives de nicotinamide,leur preparation et leur application en therapeutique |
| US20130317027A1 (en) | 2010-03-01 | 2013-11-28 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| AU2011223790A1 (en) | 2010-03-01 | 2012-08-30 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
| RU2017112522A (ru) | 2011-05-04 | 2019-01-24 | ФОРМА ТиЭм, ЭлЭлСИ | Новые соединения и композиции для ингибирования nampt |
| CA2877474A1 (en) | 2011-06-20 | 2012-12-27 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| WO2013082150A1 (en) | 2011-11-30 | 2013-06-06 | The Curators Of The University Of Missouri | Small molecule inhibitors of nicotinamide phosphoribosyltransferase (nampt) |
| WO2014074715A1 (en) | 2012-11-07 | 2014-05-15 | Genentech, Inc. | Cyclopropyl amide derivatives |
| WO2014085607A1 (en) * | 2012-11-29 | 2014-06-05 | Karyopharm Therapeutics Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
| WO2014111871A1 (en) | 2013-01-17 | 2014-07-24 | Aurigene Discovery Technologies Limited | 4,5-dihydroisoxazole derivatives as nampt inhibitors |
| EP3016946B1 (en) * | 2013-07-03 | 2022-10-12 | Karyopharm Therapeutics Inc. | Substituted benzofuranyl and benzoxazolyl compounds and pharmaceutical uses thereof |
| WO2015042414A1 (en) * | 2013-09-20 | 2015-03-26 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
| CA2921532A1 (en) | 2013-10-09 | 2015-04-16 | Eli Lilly And Company | Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors |
| US20170369470A1 (en) | 2014-12-16 | 2017-12-28 | Karyopharm Therapeutics Inc. | Cyclic Compounds and Uses Thereof |
| EP3337796A1 (en) | 2015-08-17 | 2018-06-27 | Karyopharm Therapeutics, Inc. | 3-(pyridin-3-yl)-acrylamide and n-(pyridin-3-yl)-acrylamide derivatives and their use as pak or nampt modulators |
| US20180244660A1 (en) | 2015-08-17 | 2018-08-30 | Karyopharm Therapeutics Inc. | Cyclopropylderivatives and their use as kinase inhibitors |
| HK1255438A1 (zh) | 2015-08-18 | 2019-08-16 | 卡尔约药物治疗公司 | 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 |
| WO2017117406A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof |
| WO2017117447A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
-
2016
- 2016-08-18 HK HK18114602.1A patent/HK1255438A1/zh unknown
- 2016-08-18 US US15/753,897 patent/US10363247B2/en active Active
- 2016-08-18 MA MA042655A patent/MA42655A/fr unknown
- 2016-08-18 CA CA2995380A patent/CA2995380A1/en not_active Abandoned
- 2016-08-18 EA EA201890524A patent/EA201890524A1/ru unknown
- 2016-08-18 JP JP2018509622A patent/JP2018528196A/ja active Pending
- 2016-08-18 MX MX2018001979A patent/MX2018001979A/es unknown
- 2016-08-18 CN CN201680060621.6A patent/CN108137563A/zh active Pending
- 2016-08-18 AU AU2016308829A patent/AU2016308829A1/en not_active Abandoned
- 2016-08-18 EP EP16756931.8A patent/EP3337797A1/en not_active Withdrawn
- 2016-08-18 WO PCT/US2016/047566 patent/WO2017031323A1/en not_active Ceased
-
2018
- 2018-02-08 IL IL257422A patent/IL257422A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA42655A (fr) | 2021-04-07 |
| HK1255438A1 (zh) | 2019-08-16 |
| IL257422A (en) | 2018-04-30 |
| US10363247B2 (en) | 2019-07-30 |
| MX2018001979A (es) | 2019-04-25 |
| CA2995380A1 (en) | 2017-02-23 |
| EP3337797A1 (en) | 2018-06-27 |
| JP2018528196A (ja) | 2018-09-27 |
| AU2016308829A1 (en) | 2018-03-08 |
| US20180235948A1 (en) | 2018-08-23 |
| WO2017031323A1 (en) | 2017-02-23 |
| CN108137563A (zh) | 2018-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201890524A1 (ru) | (s,e)-3-(6-аминопиридин-3-ил)-n-((5-(4-(3-фтор-3-метилпирролидин-1-карбонил)фенил)-7-(4-фторфенил)бензофуран-2-ил)метил)акриламид для лечения рака | |
| EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
| EA201890338A1 (ru) | Оксадиазольные производные, пригодные в качестве ингибиторов hdac | |
| EA201991515A1 (ru) | N-[4-фтор-5-[[(2s,4s)-2-метил-4-[(5-метил-1,2,4-оксадиазол-3-ил)метокси]-1-пиперидил]метил]тиазол-2-ил]ацетамид в качестве ингибитора oga | |
| EA201691853A1 (ru) | Агонисты мускариновых рецепторов | |
| EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
| EA201992126A1 (ru) | Ингибиторы jak, содержащие 4-членный гетероциклический амид | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| EA201690153A1 (ru) | Замещенные бензофуранильные и бензоксазолильные соединения и их применения | |
| EA201800064A1 (ru) | 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl | |
| EA201790476A1 (ru) | Аминопиридилоксипиразольные соединения | |
| EA201491012A1 (ru) | Гетероциклические ингибиторы глютаминазы | |
| EA201592199A1 (ru) | Производные бипиразола в качестве ингибиторов jak | |
| EA201690752A1 (ru) | Ингибиторы g12c kras | |
| EA201590975A1 (ru) | Ингибиторы prmt5 и их применение | |
| EA201390969A1 (ru) | Модуляторы глюкагонового рецептора | |
| UA104489C2 (uk) | Сполуки для лікування дисліпідемії та споріднених хвороб | |
| EA201590228A1 (ru) | Антагонисты 5-ht3 рецептора | |
| EA201400161A1 (ru) | Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| MA35716B1 (fr) | Formulations pharmaceutiques | |
| EA202091016A1 (ru) | Пиримидиновое соединение в качестве ингибитора jak киназы | |
| EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
| EA201990678A1 (ru) | Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2 |